scholarly journals The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets

2018 ◽  
Vol 19 (3) ◽  
pp. 831 ◽  
Author(s):  
Santa Mammana ◽  
Paolo Fagone ◽  
Eugenio Cavalli ◽  
Maria Basile ◽  
Maria Petralia ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyotrophic Lateral Sclerosis ◽  
Therapeutic Targets ◽  
Lateral Sclerosis

The comparisons of blood plasma and cerebrospinal fluid S100B protein concentrations in patients with Alzheimer`s disease, amyotrophic lateral sclerosis, and multiple sclerosis

2019 ◽  
Vol 1 ◽  
pp. 22-27
Author(s):  
J. Tarasiuk ◽  
K. Kapica-Topczewska ◽  
M. Chorąży ◽  
A. Borowik-Zaręba ◽  
B. Mroczko ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Blood Plasma ◽  
Reference Group ◽  
Central Nervous System Disorders ◽  
Lateral Sclerosis

<b>Introduction:</b>S100 calcium-binding protein B (S100B) is a biochemical marker of astroglial damage. <br/><b>Purpose:</b> To assess the pathophysiological implications of S100B concentrations in blood plasma and cerebrospinal fluid of patients with neurodegenerative central nervous system disorders. <br/><b>Materials and Methods:</b> In this study, we determined and compare S100B concentrations in blood plasma and cerebrospinal fluid obtained from subjects diagnosed with Alzheimer's disease (n=20), amyotrophic lateral sclerosis (n=12), multiple sclerosis (n=40) and the reference group (n=20), using enzyme-linked immunosorbent assay. <br/><b>Results:</b> Concentrations of S100B in plasma collected from patients diagnosed with Alzheimer's disease (252,38±183,50 pg/mL) and multiple sclerosis (164,92±250,14 pg/mL) were above laboratory standards, but in patients with amyotrophic lateral sclerosis (53,96±56,92 pg/mL) and the reference group (2,12 pg/mL) were below laboratory norms (N>75 pg/mL). Concentrations of S100B in plasma collected from patients with Alzheimer's disease (252,38±183,50 pg/mL) were significantly higher than in patients with amyotrophic lateral sclerosis (53,96±56,92 pg/mL) (p<0,029). Concentrations of S100B in CSF collected from the reference group (546,96±236,62 pg/mL) and from patients with Alzheimer's disease (587,53±189,57 pg/mL), amyotrophic lateral sclerosis (404,41±179,56 pg/mL), multiple sclerosis (462,03±146,01 pg/mL) were very similar, and none of pairwise comparisons reached statistical significance. <br/><b>Conclusions:</b> Results of our studies indicate the importance of S100B protein concentration assessment in blood in central nervous system disorders differential diagnostics.

scholarly journals Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease

2019 ◽  
Vol 10 (2) ◽  
pp. 470 ◽  
Author(s):  
Ashok K. Shetty ◽  
Raghavendra Upadhya ◽  
Leelavathi N. Madhu ◽  
Maheedhar Kodali
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyotrophic Lateral Sclerosis ◽  
Brain Aging ◽  
Lateral Sclerosis
Sign in / Sign up

Export Citation Format

Share Document